 Receptors, N-Methyl-D-Aspartate
"Receptors, N-Methyl-D-Aspartate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of ionotropic glutamate receptors characterized by affinity for N-methyl-D-aspartate. NMDA receptors have an allosteric binding site for glycine which must be occupied for the channel to open efficiently and a site within the channel itself to which magnesium ions bind in a voltage-dependent manner. The positive voltage dependence of channel conductance and the high permeability of the conducting channel to calcium ions (as well as to monovalent cations) are important in excitotoxicity and neuronal plasticity.
| Descriptor ID |
D016194
|
| MeSH Number(s) |
D12.776.157.530.400.400.500.500 D12.776.543.550.450.500.200.500 D12.776.543.585.400.500.200.500 D12.776.543.750.720.200.450.400.500
|
| Concept/Terms |
Receptors, N-Methyl-D-Aspartate- Receptors, N-Methyl-D-Aspartate
- Receptors, N Methyl D Aspartate
- N-Methyl-D-Aspartate Receptors
- N Methyl D Aspartate Receptors
- NMDA Receptors
- Receptors, N-Methylaspartate
- Receptors, N Methylaspartate
- Receptors, NMDA
- NMDA Receptor-Ionophore Complex
- NMDA Receptor Ionophore Complex
- N-Methylaspartate Receptors
- N Methylaspartate Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptors, N-Methyl-D-Aspartate".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Carrier Proteins [D12.776.157]
- Membrane Transport Proteins [D12.776.157.530]
- Ion Channels [D12.776.157.530.400]
- Ligand-Gated Ion Channels [D12.776.157.530.400.400]
- Receptors, Ionotropic Glutamate [D12.776.157.530.400.400.500]
- Receptors, N-Methyl-D-Aspartate [D12.776.157.530.400.400.500.500]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Ion Channels [D12.776.543.550.450]
- Ligand-Gated Ion Channels [D12.776.543.550.450.500]
- Receptors, Ionotropic Glutamate [D12.776.543.550.450.500.200]
- Receptors, N-Methyl-D-Aspartate [D12.776.543.550.450.500.200.500]
- Membrane Transport Proteins [D12.776.543.585]
- Ion Channels [D12.776.543.585.400]
- Ligand-Gated Ion Channels [D12.776.543.585.400.500]
- Receptors, Ionotropic Glutamate [D12.776.543.585.400.500.200]
- Receptors, N-Methyl-D-Aspartate [D12.776.543.585.400.500.200.500]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Neurotransmitter [D12.776.543.750.720]
- Receptors, Amino Acid [D12.776.543.750.720.200]
- Receptors, Glutamate [D12.776.543.750.720.200.450]
- Receptors, Ionotropic Glutamate [D12.776.543.750.720.200.450.400]
- Receptors, N-Methyl-D-Aspartate [D12.776.543.750.720.200.450.400.500]
Below are MeSH descriptors whose meaning is more specific than "Receptors, N-Methyl-D-Aspartate".
This graph shows the total number of publications written about "Receptors, N-Methyl-D-Aspartate" by people in this website by year, and whether "Receptors, N-Methyl-D-Aspartate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 2 | 1 | 3 | | 1999 | 1 | 1 | 2 | | 2000 | 2 | 0 | 2 | | 2001 | 6 | 1 | 7 | | 2002 | 6 | 0 | 6 | | 2003 | 3 | 3 | 6 | | 2004 | 1 | 3 | 4 | | 2005 | 6 | 2 | 8 | | 2006 | 3 | 5 | 8 | | 2007 | 5 | 4 | 9 | | 2008 | 4 | 0 | 4 | | 2009 | 1 | 2 | 3 | | 2010 | 6 | 1 | 7 | | 2011 | 4 | 2 | 6 | | 2012 | 2 | 3 | 5 | | 2013 | 2 | 3 | 5 | | 2014 | 5 | 7 | 12 | | 2015 | 3 | 5 | 8 | | 2016 | 8 | 3 | 11 | | 2017 | 3 | 6 | 9 | | 2018 | 2 | 4 | 6 | | 2019 | 1 | 4 | 5 | | 2020 | 1 | 1 | 2 | | 2021 | 2 | 1 | 3 | | 2022 | 1 | 1 | 2 | | 2023 | 2 | 3 | 5 | | 2024 | 4 | 1 | 5 | | 2025 | 4 | 2 | 6 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, N-Methyl-D-Aspartate" by people in Profiles.
-
Karnstedt M, Perszyk RE, Myers SJ, McDaniels E, Somorai M, Borggraefe I, Veenma DCM, Schoonjans AS, Striano P, Fantaneanu TA, Syrbe S, Park K, Chen W, Yuan H, Traynelis SF, Benke TA, Lemke JR, Krey I. Memantine treatment in individuals with GRIN gain-of-function variants is associated with improvements in behavior, development, and seizure frequency. Epilepsia. 2026 Apr; 67(4):1961-1974.
-
Teoh J, Simko J, Camp CR, Liu CJ, Wang W, Williams DJ, Ma L, Soundararajan D, Martin C, Taylor NK, François E, Petri S, Kanber A, Ravichandra A, Pero ME, Bartolini F, Swayne TC, Lutz CM, Zuberi A, Rubinstein M, Hausman-Kedem M, Yuan H, Gelinas JN, Sands TT, Harper SQ, Traynelis SF, Makinson CD, Frankel WN. Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy. Brain. 2025 Nov 04; 148(11):3973-3988.
-
Lemke JR, Eoli A, Krey I, Popp B, Strehlow V, Wittekind DA, Vuorinen AL, Aldhalaan HM, Baer S, de Saint Martin A, Hammer TB, Herman I, Hornemann F, Ingebrigtsen T, Lederer D, Lesca G, Marafie D, Mathot M, Rosenfeld JA, Møller RS, Schelhaas HJ, Stillman C, Orsini A, Patel AD, Piard J, Veggiotti P, Vlaskamp DRM, Weckhuysen S, Traynelis SF, Benke TA, Heyne HO, Syrbe S. GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. Mol Psychiatry. 2026 Jan; 31(1):374-382.
-
Lanskey JH, Jafarian A, Hughes LE, Karadag M, Kocagoncu E, Rouse MA, Adams NE, Naessens M, Raymont V, Woolrich M, Singh KD, Henson RN, Rowe JB. Alzheimer's disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography. Mol Psychiatry. 2026 Mar; 31(3):1587-1596.
-
Morabito A, Zerlaut Y, Dhanasobhon D, Berthaux E, Pinho CM, Tzilivaki A, Moneron G, Cathala L, Poirazi P, Bacci A, DiGregorio DA, Lourenço J, Rebola N. Distinct dendritic integration strategies control dynamics of inhibition in the neocortex. Neuron. 2025 Sep 17; 113(18):2962-2978.e10.
-
Camp CR, Banke TG, Xing H, Yu K, Perszyk RE, Epplin MP, Akins NS, Zhang J, Benke TA, Yuan H, Liotta DC, Traynelis SF. Selective enhancement of the interneuron network and gamma-band power via GluN2C/GluN2D NMDA receptor potentiation. J Physiol. 2025 07; 603(14):4027-4049.
-
Brown CN, Blaine RE, Barker CM, Coultrap SJ, Bayer KU. The neuroprotective ?-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIa autophosphorylation at T286 or binding to GluN2B. Mol Pharmacol. 2025 Apr; 107(4):100029.
-
Gresch A, Osthues J, Hüwel JD, Briggs JK, Berger T, Koch R, Deickert T, Beecks C, Benninger RKP, Düfer M. Resolving Spatiotemporal Electrical Signaling Within the Islet via CMOS Microelectrode Arrays. Diabetes. 2025 Mar 01; 74(3):343-354.
-
Rumian NL, Barker CM, Larsen ME, Tullis JE, Freund RK, Taslimi A, Coultrap SJ, Tucker CL, Dell'Acqua ML, Bayer KU. LTP expression mediated by autonomous activity of GluN2B-bound CaMKII. Cell Rep. 2024 10 22; 43(10):114866.
-
Prikhodko O, Freund RK, Sullivan E, Kennedy MJ, Dell'Acqua ML. Amyloid-ß Causes NMDA Receptor Dysfunction and Dendritic Spine Loss through mGluR1 and AKAP150-Anchored Calcineurin Signaling. J Neurosci. 2024 09 11; 44(37).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|